<DOC>
	<DOCNO>NCT02004587</DOCNO>
	<brief_summary>The trial investigate influence hepatic function PK gemigliptin . In additional treatment period , PK safety multiple dose gemigliptin healthy White subject investigate .</brief_summary>
	<brief_title>Influence Hepatic Impairment Pharmacokinetic ( PK ) Pharmacodynamic ( PD ) Gemigliptin PK PD After Multiple Oral Doses Healthy White Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Male female subject able understand follow instruction study available study participation . Signed informed consent . White Unwilling unable give inform consent . As result medical screening process , study physician considers subject unfit study . The subject history drug allergy contraindicate study participation . Female subject pregnant lactate . Any condition ( surgical medical ) history severe disease sequela increase risk subject affect absorption , distribution , metabolism excretion study drug otherwise</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Gemigliptin</keyword>
</DOC>